Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- 2023 Top Story in Metastatic Breast Cancer: Kicking the Can Down the Road—Delaying the Use of Chemotherapy in Hormone Receptor–Positive Metastatic Breast Cancer With Novel Endocrine and Targeted Treatment Options
- SABCS 2023: Abstract Recommendations From Dr. Reshma Mahtani for Breast Cancer
- Overall Survival and Exploratory Biomarker Analyses in Patients With HR+/HER2+ Metastatic Breast Cancer Receiving Abemaciclib Plus Trastuzumab ± Fulvestrant vs Trastuzumab Plus Chemotherapy
- Patritumab Deruxtecan, a HER3-Directed Antibody–Drug Conjugate, for Heavily Pretreated HER3-Expressing Metastatic Breast Cancer
- Overall Survival With Sacituzumab Govitecan in Patients With Pretreated, Endocrine-Resistant, HR+/HER2− Metastatic Breast Cancer
- ESMO 2023: Recommendations From Dr. Reshma Mahtani for Breast Cancer
- Efficacy and Safety of Trastuzumab Deruxtecan vs Treatment of Physician's Choice in Patients With HER2-Positive Metastatic Breast Cancer
- Outcomes of ctDNA Analysis in Patients With HR+/HER2− Advanced Breast Cancer Treated With Ribociclib Plus Endocrine Therapy
- Initial Pertuzumab Plus Trastuzumab ± Chemotherapy Followed by Trastuzumab Plus Emtansine for ERBB2+ Metastatic Breast Cancer
- Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With ER+/ERBB2− Metastatic Breast Cancer